Catalyst Pharmaceuticals (CPRX) Income from Continuing Operations (2010 - 2026)

Catalyst Pharmaceuticals has reported Income from Continuing Operations for 17 years, with the latest figure at 63734000.0 in Q1 2026.

• For the quarter ending Q1 2026, Income from Continuing Operations rose 12.33% year-over-year to 63734000.0; the trailing twelve-month figure through Mar 2026 stood at 214558000.0 (up 14.19% YoY), and the FY2025 full-year result was 207561000.0, up 34.4% from the prior year.
• Income from Continuing Operations for Q1 2026 stood at 63734000.0, up from 45933000.0 in the prior quarter.
• The five-year high for Income from Continuing Operations was 63734000.0 in Q1 2026, with the low at 30764000.0 in Q3 2023.
• Historically, Income from Continuing Operations has averaged 33599823.53 across 5 years, with a median of 37762000.0 in 2023.
• Annual changes were most pronounced in 2022 — Income from Continuing Operations surged 267.96% — and 2023, when it plunged 235.24%.
• Catalyst Pharmaceuticals' Income from Continuing Operations stood at 34253000.0 in 2022, then slumped by 50.26% to 17039000.0 in 2023, then jumped by 172.8% to 46483000.0 in 2024, then fell by 1.18% to 45933000.0 in 2025, then soared by 38.75% to 63734000.0 in 2026.
• The last three Income from Continuing Operations figures came in at 63734000.0 (Q1 2026), 45933000.0 (Q4 2025), and 52783000.0 (Q3 2025), per Business Quant data.